Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93868Research ArticlePreduprezhdenie diabeticheskogo porazheniya pochek: fokus na antigipertenzivnye preparatyFominV. V-SvistunovA. A-15052013155565928122021Copyright © 2013, Consilium Medicum2013[Platinga L.C, Crews D.C, Coresh J et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 2010; 5: 673–82.][Шестакова М.В., Чугунова Л.А., Шамхалова М.Ш. и др. Диабетическая нефропатия: факторы риска быстрого прогрессирования почечной недостаточности. Тер. архив. 1999; 6: 38–41.][Matsushita K, van der Velde M, Astor B.C et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all - cause and cardiovascular mortality in general population cohorts: A collaborative meta - analysis. Lancet 2010; 375: 2073–81.][EUCLID Study Group. Randomized placebo - controlled trial of lisinopril in normotensive patients with normotensive diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997; 347: 1787–92.][Brenner B.M, Cooper M.E, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.][Perkovic Lv.J, Foote C.V, Craig M.E et al. Antihypertensive agents for preventing diabetic kidney disease (review). Cochrane Library 2012: Issue 12.][Patel A, Mac Mahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (The ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829–40.][Haller H, Ito S, Izzo J.L et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907–17.][Bilous R, Chaturvedi N, Sjolie A.K et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009; 151: 11–20.][Savarese G, Constanzo P, Clelend J.G.F et al. A meta - analysis reporting effect of angiotensin - converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. JACC 2013; 61 (2): 131–42.][HOPE Study Group. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE Study and MICRO - HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253–9.][Parving H-H, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8.][Makino H, Haneda M, Babazono T et al. INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30 (6): 1577–8.][Menne J, Izzo J.L, Ito S et al. ROADMAP investigators. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens 2012; 30 (4): 811–8.][Tobe S.W, Clase C.M, Gao P et al. ONTARGET and TRANSCEND Investigators. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people with high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011; 123 (10): 1098–107.][Ruggenenti P, Fassi A, Ilieva A.P et al. Preventing microalbuminuria in type 2 diabetes mellitus. N Engl J Med 2004; 351 (19): 1941–51.][Ritz E, Orth S.R. Nephropathy in type 2 diabetes mellitus. N Engl J Med 1999; 341 (15): 1127–33.][Raebel M.A. Hyperkalemia associated with use of angiotensin - converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther 2012; 30 (3): e156–e166.]